Glutamic acid
Glutamic acid is aspartate with one more methylene group, and that extra carbon changes what it can reach. It is the most common acidic residue in proteins, the brain’s main excitatory neurotransmitter, and the source of the taste called umami.
- Molecular formula
- C5H9NO4
- Molar mass
- 147.13 g/mol
- Residue mass, average
- 129.1155 Da
- Residue mass, monoisotopic
- 129.04259 Da
- pKa (α-COOH / α-NH₃⁺)
- 2.19 / 9.67
- Side-chain pKa
- 4.25
- Isoelectric point
- 3.22
- CAS number
- 56-86-0
Structure
- H
- C
- N
- O
- S
The 3D geometry represents the neutral experimental record; the pH control applies to the skeletal view.
The skeletal view begins with the zwitterion at pH 7.
A longer acidic arm
Two methylene groups separate the carboxylate from the backbone, against one for aspartate. The extra reach makes glutamate better at bridging to a distant partner and slightly less prone to attacking its own backbone.
Slightly weaker acid
Its side-chain pKa of 4.25 is higher than aspartate’s 3.65, because the charge sits further from the electron-withdrawing backbone. Both are fully ionised at physiological pH.
Charge and pH
A low isoelectric point
Like aspartate, glutamate has two acidic groups and one basic, giving an isoelectric point of 3.22. Above pH 5 it is reliably negative.
In a sequence
Glutamate is the standard way to add negative charge and solubility to a peptide without adding much bulk. Poly-glutamate tags are used for exactly that purpose.
Properties
| IUPAC name | (2S)-2-aminopentanedioic acid |
|---|---|
| Three-letter code | Glu |
| One-letter code | E |
| Class | Negatively charged |
| Dietary requirement | Non-essential |
| CAS | 56-86-0 |
| PubChem CID | 33032 |
| InChIKey | WHUUTDBJXJRKMK-VKHMYHEASA-N |
| Formula | C5H9NO4 |
|---|---|
| Molar mass | 147.13 g/mol |
| Residue mass, average | 129.1155 Da |
| Residue mass, monoisotopic | 129.04259 Da |
| Side chain | −CH₂CH₂COO⁻ |
| pKa, α-carboxyl | 2.19 |
| pKa, α-amino | 9.67 |
| pKa, side chain | 4.25 |
| Isoelectric point | 3.22 |
| Hydropathy | -3.5 |
| Volume ų | 109 |
Genetic code and occurrence
Codons
- GAA
- GAG
Codons are written as mRNA; U is uracil.
| Frequency in proteins | 6.75% |
|---|---|
| Number of codons | 2 |
| Dietary requirement | Non-essential |
Role in peptides
Pyroglutamate formation
An N-terminal glutamate or glutamine can cyclise to pyroglutamate, blocking the free amino group and subtracting 18 or 17 Da. Some peptides use this deliberately; in others it is an unwanted modification.
Metal binding
Like aspartate, glutamate carboxylates coordinate metal ions, and clusters of the two are the usual architecture of a calcium binding site.
Helix salt bridges
Glutamate paired with lysine four positions along stabilises an alpha helix, a pattern used routinely in designed peptides.
Biological role
The main excitatory neurotransmitter
Glutamate carries most of the excitatory signalling in the central nervous system, acting at AMPA, NMDA and kainate receptors. Too much of it outside the cell is toxic, a process called excitotoxicity.
The nitrogen hub
Glutamate sits at the junction of amino acid and carbohydrate metabolism. Transamination moves nitrogen on and off it, which is how the body shuffles amine groups between amino acids.
Umami
Free glutamate is what the umami taste receptor detects, and monosodium glutamate is simply its sodium salt. The glutamate in a tomato and the glutamate in MSG are the same molecule.
Kept out of the brain
Dietary glutamate does not raise brain glutamate appreciably. The blood-brain barrier and the gut both metabolise it heavily, which is central to the safety argument about MSG.
Research evidence
| Area | Summary | Evidence |
|---|---|---|
| MSG safety | Regulatory reviews have repeatedly found monosodium glutamate acceptable at normal intakes, and controlled challenge studies have not reproduced the symptom cluster once attributed to it. Public perception and the evidence remain some distance apart. | Well studied |
| Excitotoxicity in disease | Glutamate handling is implicated in stroke, epilepsy and neurodegeneration, and several licensed drugs act on glutamate receptors. This is mechanism and pharmacology rather than nutrition. | Established |
| Glutamate as a supplement | Supplemental L-glutamic acid has little human trial literature. Dietary protein supplies large amounts and no deficiency is described. | Not studied |
These summaries describe research on amino acids and related molecules, not evidence for Aminos products. Aminos products are laboratory research reagents, not supplements or medicines.
Laboratory notes
Pyroglutamate at the N terminus
If a sequence begins with glutamate or glutamine, expect some pyroglutamate to form, particularly at slightly acidic pH and raised temperature. Sequencing by Edman degradation fails on a blocked terminus.
Anion exchange behaviour
Glutamate-rich peptides bind anion exchangers at neutral pH and are eluted with increasing salt.
Poly-glutamate for solubility
Adding a short run of glutamates to a poorly soluble sequence is a standard trick, though it changes the isoelectric point substantially.
Invisible at 280 nm
Glutamate contributes nothing to absorbance at 280 nm.
References
Sources used for the data on this page.
- PubChem CID 33032: L-Glutamic acidIdentifiers, formula and physical data.
- pKa and pI values for the twenty amino acidsDepartment of Chemistry, University of Calgary.
Reference information only. This page describes the chemistry and biology of an amino acid. Nothing here is medical, nutritional or dosing advice. Aminos compounds are sold strictly for laboratory research use and are not medicines.